Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
NCT07029009 on ClinicalTrials.gov · last registry update 2025-12-17
A small phase 2 — 50 participants, against a typical 110. Its estimated completion date, August 2026, has passed with no update to the record. Primary outcome, as filed: Blood sugar control - HbA1C. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.
- Status
- RECRUITING
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Mansa
- Sponsor type
- Other
- Enrollment
- 50
- Started
- 2025-05-08
- Primary completion
- 2026-08 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Blood sugar control - HbA1C
Conditions studied
Maturity Onset Diabetes of the Young
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.